Health Catalyst (NASDAQ:HCAT) has been reviewed by 7 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $11.29, down 8.43% from the previous $12.33. Analysts have adjusted their ratings and price targets in response to company performance and market dynamics, with some raising and others lowering their expectations. Health Catalyst is a provider of data and analytics technology and services to healthcare organizations, with a market cap below the industry average and a revenue growth rate of 7.93%. The company has a high net margin of -29.86% and an ROE of -5.71%, with a debt-to-equity ratio of 0.65.